Herantis Pharma Plc, a clinical-stage biotechnology company, has secured $8.0 million in new funding from investors. This capital infusion marks a significant development for the company as it continues to advance its pipeline of disease-modifying therapies for Parkinson’s disease. The funding round underscores investor confidence in Herantis’s approach to addressing neurodegenerative conditions and its lead product candidate.
Herantis Pharma Plc is dedicated to developing innovative treatments for Parkinson’s disease. Its primary focus is HER-096, a first-in-class small peptide designed to leverage the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF). HER-096 offers the convenience of subcutaneous administration, a key advantage for patient adherence. The company previously completed a Phase 1b clinical trial for HER-096, which demonstrated the therapy to be generally safe and well tolerated in Parkinson’s disease patients.
The newly raised $8.0 million will be instrumental in supporting Herantis Pharma Plc’s strategic growth initiatives and advancing its clinical development programs. Specifically, the company plans to use these funds to progress HER-096 towards a pivotal Phase 2 clinical trial. This trial, anticipated to commence in 2026, will evaluate the efficacy, safety, and tolerability of HER-096 in early-stage Parkinson’s patients, moving closer to potentially offering a new therapeutic option.
This investment positions Herantis Pharma Plc to accelerate its mission of bringing disease-modifying treatments to patients suffering from Parkinson’s disease. The company, listed on the Nasdaq First North Growth Market Finland, is focused on leveraging this capital to achieve key clinical milestones and further solidify its position in the neurodegenerative disease landscape, aiming to make a meaningful impact on patient lives.
.png&w=3840&q=75)
